These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32294158)

  • 1. Phase 1 study of lenzilumab, a recombinant anti-human GM-CSF antibody, for chronic myelomonocytic leukemia.
    Patnaik MM; Sallman DA; Mangaonkar AA; Heuer R; Hirvela J; Zblewski D; Al-Kali A; Binder M; Balasis ME; Newman H; Letson C; Kruer TL; Gangat N; Komrokji RS; Tefferi A; Lo A; Shih T; Durrant C; List AF; Padron E
    Blood; 2020 Aug; 136(7):909-913. PubMed ID: 32294158
    [No Abstract]   [Full Text] [Related]  

  • 2. Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical Trial.
    Kushner BH; Cheung IY; Modak S; Basu EM; Roberts SS; Cheung NK
    JAMA Oncol; 2018 Dec; 4(12):1729-1735. PubMed ID: 30326045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
    Shemesh CS; Agarwal P; Lu T; Lee C; Dere RC; Li X; Li C; Jin JY; Girish S; Miles D; Lu D
    Cancer Chemother Pharmacol; 2020 May; 85(5):831-842. PubMed ID: 32222808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.
    Nehra J; Bradbury PA; Ellis PM; Laskin J; Kollmannsberger C; Hao D; Juergens RA; Goss G; Wheatley-Price P; Hotte SJ; Gelmon K; Tinker AV; Brown-Walker P; Gauthier I; Tu D; Song X; Khan A; Seymour L; Smoragiewicz M
    Invest New Drugs; 2020 Oct; 38(5):1442-1447. PubMed ID: 32020438
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor is toxic to blasts from patients with juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Frankel AE; Lilly M; Kreitman R; Hogge D; Beran M; Freedman MH; Emanuel PD; McLain C; Hall P; Tagge E; Berger M; Eaves C
    Blood; 1998 Dec; 92(11):4279-86. PubMed ID: 9834234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin 10 inhibits growth and granulocyte/macrophage colony-stimulating factor production in chronic myelomonocytic leukemia cells.
    Geissler K; Ohler L; Födinger M; Virgolini I; Leimer M; Kabrna E; Kollars M; Skoupy S; Bohle B; Rogy M; Lechner K
    J Exp Med; 1996 Oct; 184(4):1377-84. PubMed ID: 8879210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hu3F8 for resistant or recurrent neuroblastoma.
    Burki TK
    Lancet Oncol; 2018 Nov; 19(11):e583. PubMed ID: 30269905
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of proliferation and induction of apoptosis in juvenile myelomonocytic leukemic cells by the granulocyte-macrophage colony-stimulating factor analogue E21R.
    Iversen PO; Rodwell RL; Pitcher L; Taylor KM; Lopez AF
    Blood; 1996 Oct; 88(7):2634-9. PubMed ID: 8839857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours.
    Attard G; Kitzen J; Blagden SP; Fong PC; Pronk LC; Zhi J; Zugmaier G; Verweij J; de Bono JS; de Jonge M
    Br J Cancer; 2007 Nov; 97(10):1338-43. PubMed ID: 18000498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors.
    Shimizu T; Seto T; Hirai F; Takenoyama M; Nosaki K; Tsurutani J; Kaneda H; Iwasa T; Kawakami H; Noguchi K; Shimamoto T; Nakagawa K
    Invest New Drugs; 2016 Jun; 34(3):347-54. PubMed ID: 27000274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of low doses of recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with myelodysplastic syndromes.
    Estey EH; Kurzrock R; Talpaz M; McCredie KB; O'Brien S; Kantarjian HM; Keating MJ; Deisseroth AB; Gutterman JU
    Br J Haematol; 1991 Mar; 77(3):291-5. PubMed ID: 2012752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A preliminary study of the anti-κ myeloma antigen monoclonal antibody KappaMab (MDX-1097) in pretreated patients with κ-restricted multiple myeloma.
    Spencer A; Walker P; Asvadi P; Campbell DH; Reed K; Herbert BR; Breen EJ; Copeman MC; Dunn RD
    Blood Cancer J; 2019 Jul; 9(8):58. PubMed ID: 31366914
    [No Abstract]   [Full Text] [Related]  

  • 13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
    Papp KA; Gooderham M; Jenkins R; Vender R; Szepietowski JC; Wagner T; Hunt B; Souberbielle B;
    Br J Dermatol; 2019 Jun; 180(6):1352-1360. PubMed ID: 30207587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience.
    Autore F; Fresa A; Innocenti I; Tomasso A; Morelli F; Corbingi A; Sorà F; Laurenti L
    Hematol Oncol; 2019 Dec; 37(5):641-643. PubMed ID: 31604368
    [No Abstract]   [Full Text] [Related]  

  • 15. GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia: A Case-Cohort Study.
    Temesgen Z; Assi M; Shweta FNU; Vergidis P; Rizza SA; Bauer PR; Pickering BW; Razonable RR; Libertin CR; Burger CD; Orenstein R; Vargas HE; Palraj R; Dababneh AS; Chappell G; Chappell D; Ahmed O; Sakemura R; Durrant C; Kenderian SS; Badley AD
    Mayo Clin Proc; 2020 Nov; 95(11):2382-2394. PubMed ID: 33153629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unplugging JAK/STAT in Chronic Myelomonocytic Leukemia.
    Solary E
    Clin Cancer Res; 2016 Aug; 22(15):3707-9. PubMed ID: 26979390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial.
    Taylor PC; Saurigny D; Vencovsky J; Takeuchi T; Nakamura T; Matsievskaia G; Hunt B; Wagner T; Souberbielle B;
    Arthritis Res Ther; 2019 Apr; 21(1):101. PubMed ID: 30999929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of granulocyte-macrophage colony-stimulating factor prevents dissemination and induces remission of juvenile myelomonocytic leukemia in engrafted immunodeficient mice.
    Iversen PO; Lewis ID; Turczynowicz S; Hasle H; Niemeyer C; Schmiegelow K; Bastiras S; Biondi A; Hughes TP; Lopez AF
    Blood; 1997 Dec; 90(12):4910-7. PubMed ID: 9389708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase Ia/Ib trial of anti-GD2 chimeric monoclonal antibody 14.18 (ch14.18) and recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) in metastatic melanoma.
    Murray JL; Kleinerman ES; Jia SF; Rosenblum MG; Eton O; Buzaid A; Legha S; Ross MI; Thompson L; Mujoo K; Rieger PT; Saleh M; Khazaeli MB; Vadhan-Raj S
    J Immunother Emphasis Tumor Immunol; 1996 May; 19(3):206-17. PubMed ID: 8811495
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial.
    Atkins MB; Plimack ER; Puzanov I; Fishman MN; McDermott DF; Cho DC; Vaishampayan U; George S; Olencki TE; Tarazi JC; Rosbrook B; Fernandez KC; Lechuga M; Choueiri TK
    Lancet Oncol; 2018 Mar; 19(3):405-415. PubMed ID: 29439857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.